// App-Quantinova.ai

3047 : Safety and tolerability results from a phase I study of MEDI4736, a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib in patients (pts) with non-small-cell lung cancer (NSCLC).

Researchers

Presenter

  • Ben C. Creelan

Principal Investigators

  • Laura Q. Chow

  • Joyson Joseph Karakunnel

  • Don Lynn Gibbons

  • Dong-Wan Kim

  • Sang-We Kim

  • Tammie Yeh

Medical Centers

  • AstraZeneca, Waltham, MA

  • Seoul National University Hospital, Seoul, South KoreaDepartment of Medicine, Division of Oncology, University of Washington, Seattle, WAMedImmune, Gaithersburg, MD

  • Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

  • H. Lee Moffitt Cancer Center & Research Institute, Riverview, FL

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non Small Cell Lung cancer

  • Dyspnea

  • Solid malignancies

Biomarkers

  • Alanine transaminase

  • Circulating tumor cells

  • Programmed death-ligand 1

  • Epidermal growth factor receptor

Drug/Treatment

  • gefitinib

  • Durvalumab

Outcome

  • N/A

Study Design

  • pharmacokinetics

Phase

  • I

Study Id's

  • NCT02088112

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved